Analysis of Adverse Drug Reactions in Dementia Patients
Author Information
Author(s): Mao Jieyu, Yamakawa Miyae, Takeya Yasushi
Primary Institution: Osaka University
Hypothesis
Dementia patients are at increased risk for adverse drug reactions due to polypharmacy and communication challenges.
Conclusion
The study found that dementia-related adverse drug reactions are significant, with a notable peak in reports around 2023.
Supporting Evidence
- The most reported ADRs included death, drug ineffective, off label use, and aggression.
- Exelon Patch was frequently reported to cause ADRs, particularly associated with death.
- The median time from treatment initiation to ADR occurrence was 20 days.
- 38.2% of reports indicated hospitalization as an outcome.
Takeaway
People with dementia often have problems with their medications, and this study looked at reports of bad reactions to those drugs over ten years.
Methodology
The study analyzed 23,519 ADR reports from the FDA Adverse Event Reporting System database, using data cleansing and imputation techniques.
Potential Biases
Potential bias in reporting as consumers and medical professionals may have different motivations for reporting ADRs.
Limitations
The study relies on reported data, which may not capture all adverse drug reactions experienced by patients.
Participant Demographics
Reports were primarily from consumers (33.4%) and medical doctors (30.1%).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website